E
RAMM Pharma Corp.
RAMM
CNSX
E
Sell
3/7/2025Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D- on 3/7/2025 due to a decline in the volatility index and total return index.
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D- on 3/7/2025 due to a decline in the volatility index and total return index.
D
Sell
2/19/2025Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D- from E+ on 2/19/2025 due to a major increase in the growth index, total return index and volatility index. EBIT increased 43.55% from -$1.31M to -$742.2, earnings per share increased from -$0.0107 to -$0.0061, and total revenue increased 3.44% from $852.9 to $882.2.
RAMM Pharma Corp. (RAMM) was upgraded to D- from E+ on 2/19/2025 due to a major increase in the growth index, total return index and volatility index. EBIT increased 43.55% from -$1.31M to -$742.2, earnings per share increased from -$0.0107 to -$0.0061, and total revenue increased 3.44% from $852.9 to $882.2.
E
Sell
12/5/2023Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D- on 12/5/2023 due to a decline in the volatility index.
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D- on 12/5/2023 due to a decline in the volatility index.
D
Sell
11/20/2023Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D- from E+ on 11/20/2023 due to an increase in the volatility index and total return index.
RAMM Pharma Corp. (RAMM) was upgraded to D- from E+ on 11/20/2023 due to an increase in the volatility index and total return index.
E
Sell
5/17/2023Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D- on 5/17/2023 due to a decline in the volatility index and total return index.
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D- on 5/17/2023 due to a decline in the volatility index and total return index.
D
Sell
5/2/2023Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D- from E+ on 5/2/2023 due to an increase in the volatility index, growth index and total return index.
RAMM Pharma Corp. (RAMM) was upgraded to D- from E+ on 5/2/2023 due to an increase in the volatility index, growth index and total return index.
E
Sell
4/6/2023Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D- on 4/6/2023 due to a decline in the volatility index.
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D- on 4/6/2023 due to a decline in the volatility index.
D
Sell
4/3/2023Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D- from E+ on 4/3/2023 due to an increase in the volatility index.
RAMM Pharma Corp. (RAMM) was upgraded to D- from E+ on 4/3/2023 due to an increase in the volatility index.
E
Sell
3/14/2023Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
D
Sell
3/6/2023Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to D- from D on 3/6/2023 due to a major decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0073 to -$0.101, EBIT declined 142.93% from -$916.7 to -$2.23M, and operating cash flow declined 126.19% from -$671.7 to -$1.52M.
RAMM Pharma Corp. (RAMM) was downgraded to D- from D on 3/6/2023 due to a major decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0073 to -$0.101, EBIT declined 142.93% from -$916.7 to -$2.23M, and operating cash flow declined 126.19% from -$671.7 to -$1.52M.
D
Sell
2/9/2023Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
RAMM Pharma Corp. (RAMM) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index and volatility index.
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
9/30/2022Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D from D- on 9/30/2022 due to a large increase in the growth index and solvency index. Debt to equity declined from 0.02 to 0, the quick ratio increased from 4.77 to 7.61, and operating cash flow increased 54.95% from -$1.49M to -$671.8.
RAMM Pharma Corp. (RAMM) was upgraded to D from D- on 9/30/2022 due to a large increase in the growth index and solvency index. Debt to equity declined from 0.02 to 0, the quick ratio increased from 4.77 to 7.61, and operating cash flow increased 54.95% from -$1.49M to -$671.8.
D
Sell
6/29/2022Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to D- from D on 6/29/2022 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 65.89% from -$898.9 to -$1.49M, and total revenue declined 7.26% from $744.8 to $690.7.
RAMM Pharma Corp. (RAMM) was downgraded to D- from D on 6/29/2022 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 65.89% from -$898.9 to -$1.49M, and total revenue declined 7.26% from $744.8 to $690.7.
D
Sell
6/21/2022Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D from D- on 6/21/2022 due to an increase in the volatility index.
RAMM Pharma Corp. (RAMM) was upgraded to D from D- on 6/21/2022 due to an increase in the volatility index.
D
Sell
6/2/2022Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to D- from D on 6/2/2022 due to a decline in the volatility index and total return index.
RAMM Pharma Corp. (RAMM) was downgraded to D- from D on 6/2/2022 due to a decline in the volatility index and total return index.
D
Sell
5/16/2022Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D from E+ on 05/16/2022.
RAMM Pharma Corp. (RAMM) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/4/2022Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index.
RAMM Pharma Corp. (RAMM) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index.
E
Sell
5/1/2022Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
D
Sell
4/21/2022Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D from E+ on 04/21/2022.
RAMM Pharma Corp. (RAMM) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D on 4/20/2022 due to a major decline in the growth index, solvency index and volatility index. The quick ratio declined from 6.37 to 4.6, and total revenue declined 10.51% from $832.3 to $744.8.
RAMM Pharma Corp. (RAMM) was downgraded to E+ from D on 4/20/2022 due to a major decline in the growth index, solvency index and volatility index. The quick ratio declined from 6.37 to 4.6, and total revenue declined 10.51% from $832.3 to $744.8.
D
Sell
3/25/2022Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D from D- on 3/25/2022 due to a significant increase in the growth index and valuation index. Earnings per share increased from -$0.0246 to -$0.0136, EBIT increased 4.31% from -$1.76M to -$1.69M, and total revenue increased 2.39% from $812.9 to $832.3.
RAMM Pharma Corp. (RAMM) was upgraded to D from D- on 3/25/2022 due to a significant increase in the growth index and valuation index. Earnings per share increased from -$0.0246 to -$0.0136, EBIT increased 4.31% from -$1.76M to -$1.69M, and total revenue increased 2.39% from $812.9 to $832.3.
D
Sell
11/8/2021Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to D- from D on 11/8/2021 due to a large decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0034 to -$0.0246, EBIT declined 87.01% from -$942.9 to -$1.76M, and total revenue declined 3.79% from $844.9 to $812.9.
RAMM Pharma Corp. (RAMM) was downgraded to D- from D on 11/8/2021 due to a large decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0034 to -$0.0246, EBIT declined 87.01% from -$942.9 to -$1.76M, and total revenue declined 3.79% from $844.9 to $812.9.
D
Sell
9/29/2021Downgrade
RAMM Pharma Corp. (RAMM) was downgraded to D from D+ on 9/29/2021 due to a decline in the total return index, volatility index and growth index. Operating cash flow declined 24.53% from -$755.5 to -$940.8, and EBIT declined 3.95% from -$906.7 to -$942.5.
RAMM Pharma Corp. (RAMM) was downgraded to D from D+ on 9/29/2021 due to a decline in the total return index, volatility index and growth index. Operating cash flow declined 24.53% from -$755.5 to -$940.8, and EBIT declined 3.95% from -$906.7 to -$942.5.
D
Sell
6/1/2021Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D+ from D on 6/1/2021 due to a large increase in the total return index, growth index and volatility index. EBIT increased 52.39% from -$1.9M to -$906.7, and earnings per share increased from -$0.0179 to -$0.0113.
RAMM Pharma Corp. (RAMM) was upgraded to D+ from D on 6/1/2021 due to a large increase in the total return index, growth index and volatility index. EBIT increased 52.39% from -$1.9M to -$906.7, and earnings per share increased from -$0.0179 to -$0.0113.
D
Sell
12/1/2020Upgraded
RAMM Pharma Corp. (RAMM) was upgraded to D from D- on 12/1/2020 due to a noticeable increase in the total return index, volatility index and valuation index.
RAMM Pharma Corp. (RAMM) was upgraded to D from D- on 12/1/2020 due to a noticeable increase in the total return index, volatility index and valuation index.
D
Sell
8/3/2020Upgraded
Ramm Pharma Holdings Corp. (RAMM) was upgraded to D- from E on 8/3/2020 due to an increase in the volatility index and total return index.
Ramm Pharma Holdings Corp. (RAMM) was upgraded to D- from E on 8/3/2020 due to an increase in the volatility index and total return index.
E
Sell
7/1/2020None
RAMM Pharma Corp. (RAMM) was downgraded to E from U on 07/01/2020.
RAMM Pharma Corp. (RAMM) was downgraded to E from U on 07/01/2020.
